Securities code: 688656 securities abbreviation: Hob Biotech Group Corp.Ltd(688656) Announcement No.: 2022-008 Hob Biotech Group Corp.Ltd(688656)
About the resignation of senior managers and core technicians
And the announcement of identifying core technicians
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law. Important content tips:
Mr. Zhang Hewen, deputy general manager, core technician and senior vice president of supply chain strategic planning of Hob Biotech Group Corp.Ltd(688656) (hereinafter referred to as “the company”, ” Hob Biotech Group Corp.Ltd(688656) “), applied for resignation as senior vice president of supply chain strategic planning of the company for personal reasons. Mr. Zhang Hewen also applied to the board of directors of the company for resignation as deputy general manager, After his resignation, Mr. Zhang Hewen no longer held other positions in the company.
After Mr. Zhang Hewen leaves office, Ms. sun Guojing, vice president of R & D of the company and Ms. Huang Xiaohua, vice president of supply chain of the company are jointly responsible for his work. Mr. Zhang Hewen’s resignation will not have a substantive impact on the company’s technology R & D, production and operation, and will not affect the integrity of the company’s core technology and its patent right.
The company identified Ms. sun Guojing, vice president of R & D, as the core technical personnel of the company based on her resume and her leadership in R & D projects and business development.
1、 Details of Mr. Zhang Hewen’s resignation
Mr. Zhang Hewen, deputy general manager, core technician and senior vice president of supply chain strategic planning of the company, recently applied for resignation from all positions of the company for personal reasons. After his resignation, Mr. Zhang Hewen no longer held any position of the company.
Mr. Zhang Hewen, without the right of permanent residence in China. Born in 1973, he graduated from Hangzhou business college with a master’s degree in food science. He once served as the assistant to the general manager of Beijing beiaikang Biotechnology Co., Ltd., the director of the service center of super array company in Maryland, the manager of the production department of CITIC Yates Diagnostic Reagent Co., Ltd. and the deputy general manager of Shanghai punus group. Served as Hob Biotech Group Corp.Ltd(688656) deputy general manager from May 2012 to February 2022.
Mr. Zhang Hewen’s resignation will not affect the integrity of the company’s core technology and the progress of the company’s existing R & D projects.
As of the disclosure date of this announcement, Mr. Zhang Hewen indirectly holds 0.45% of the shares of the company through Suzhou wairun investment management partnership (limited partnership) (hereinafter referred to as “Suzhou wairun”), Suzhou wairun holds 7730657.00 shares of the company, accounting for 12.26% of the total share capital of the company, and Mr. Zhang Hewen holds 3.69% of the capital contribution of Suzhou wairun. Mr. Zhang Hewen will continue to abide by the relevant provisions of the Listing Rules of the science and Innovation Board of Shanghai Stock Exchange, the implementation rules for the reduction of shares held by shareholders, directors, supervisors and senior managers of companies listed on Shanghai Stock Exchange and the relevant commitments made by the company during the initial public offering of shares.
(I) details of core technicians
Mr. Zhang Hewen joined the company in May 2012 and successively served as the head of the company’s supply chain module and the head of R & D module. He is committed to the construction of allergen and autoimmune products, and is responsible for the continuous improvement of production system, pilot transformation, process improvement, quality management system and product R & D.
(II) R & D projects and patented technologies involved
During his tenure, Mr. Zhang Hewen mainly participated in the R & D of the company’s diagnostic reagents for allergic and autoimmune diseases. At present, the technicians of the company’s above product R & D projects also include core technicians Ms. sun Guojing, Mr. Chen Xiaosan, Ms. Li Yonghong, Mr. Qian Lin and many other R & D personnel. Mr. Zhang Hewen’s resignation will not affect the promotion and implementation of the above projects.
The patents and other intellectual property rights that Mr. Zhang Hewen participated in and applied for during his work are job achievements. As of the disclosure date of the announcement, the ownership of the intellectual property rights formed by these job achievements belongs to the company or its subsidiaries, and there are no disputes or potential disputes related to job achievements and intellectual property rights, Mr. Zhang Hewen’s resignation will not affect the integrity of the company’s patents and other intellectual property rights. In addition to the above, Mr. Zhang Hewen has not participated in other research projects or involved in the R & D of other core technologies of the company, which will not affect the progress of the company’s existing R & D projects.
(III) confidentiality agreement
The company has signed a confidentiality agreement with Mr. Zhang Hewen. According to the confidentiality agreement signed with the company, Mr. Zhang Hewen shall be obliged to keep confidential the technical secrets or business secrets of the company that he contacts and knows during his tenure in the company. It is not allowed to disclose, inform, publish, publish, impart, transfer or make any third party know the technical secrets or trade secrets belonging to the company in any other way. As of the date of this announcement, the company has not found that Mr. Zhang Hewen went to work in a competitor’s office after his resignation, and has not found that Mr. Zhang Hewen violated the confidentiality agreement.
2、 The impact of Mr. Zhang Hewen’s resignation on the company
Mr. Zhang Hewen has completed the handover with Ms. sun Guojing, vice president of R & D of the company. At present, the undertaking personnel of the R & D team have the ability and conditions to follow up the follow-up R & D work. Mr. Zhang Hewen’s resignation will not have a material impact on the company’s technology R & D, core competitiveness and sustainable operation ability.
At the end of 2019, 2020 and 2021, the number of R & D technicians of the company was 61, 62 and 84 respectively, and the number of R & D technicians of the company increased year by year; At the end of 2019, 2020, 2021 and as of the disclosure date of this announcement, the number of core technical personnel of the company is 5, 5, 4 and 4 respectively, and the personnel are stable. The specific personnel are as follows:
Name of annual core technical personnel
At the end of 2019, Zhang Hewen, Chen Xiaosan, Liu Le, Qian Lin and Li Yonghong
By the end of 2020, Zhang Hewen, Chen Xiaosan, Liu Le, Qian Lin and Li Yonghong
At the end of 2021, Zhang Hewen, Chen Xiaosan, Qian Lin and Li Yonghong
As of the disclosure date of the announcement, Chen Xiaosan, Qian Lin, Li Yonghong and sun Guojing
At present, the company’s technology R & D and daily operation are carried out normally. The company’s R & D team and core technicians are relatively stable. The existing R & D team and core technicians can support the continuous R & D of the company’s core technology in the future. The overall R & D strength has not changed significantly due to the departure of Mr. Zhang Hewen.
3、 Measures taken by the company
The company decided that Ms. sun Guojing, vice president of R & D, and Ms. Huang Xiaohua, vice president of supply chain, would be jointly responsible for taking over the relevant work of Mr. Zhang Hewen. The company identified Ms. sun Guojing as the company’s core technical personnel in combination with her resume, leadership and participation in the company’s core technology research and development and other relevant factors. Ms. sun Guojing, Chinese nationality, permanent residency in the United States. Born in 1972, he graduated from the Academy of Military Medical Sciences with a doctorate. He joined the Academy of Military Medical Sciences in 2000 and served as an assistant researcher. From May 2005 to March 2018, he served as Beijing Strong Biotechnologies Inc(300406) senior R & D personnel, technical director of immunoassay and assistant to the general manager.
From March 2018 to July 2020, he served as advisor Director of Inc biological laboratory, engaged in the research and development of in vitro diagnostic reagents for more than 20 years. From November 2020 to now, he has served as the vice president of R & D of the company, fully participated in and was responsible for the running in matching, optimization and verification of allergy and self free chemiluminescence reagents and automatic chemiluminescence instrument.
Ms. Huang Xiaohua, Chinese nationality, has no right of permanent residence abroad. Born in 1974, he graduated from Tsinghua University with a master’s degree. In 1997, he joined Shenzhen Weiwu Guangming Biological Products Co., Ltd. as the quality director, and served as the head of Beijing factory of Thermo Fisher Biotechnology Co., Ltd. from November 2002 to December 2017. From January 2018 to may 2021, he served as the deputy general manager of Beijing Bohui Innovation Biotechnology Group Co.Ltd(300318) manufacturing operation center. From June 2021 to now, he has served as vice president of project and system management and vice president of supply chain of Hob Biotech Group Corp.Ltd(688656) company. He has been engaged in the production and quality management of in vitro diagnostic reagents for more than 20 years.
At present, the company’s R & D department has a complete structure and sufficient reserve personnel, and the existing R & D department personnel have corresponding professional skills. For Mr. Zhang Hewen’s resignation, the company’s countermeasures are sufficient and feasible. Mr. Zhang Hewen’s resignation will not have a substantive impact on the company’s core technology and production and operation.
4、 Opinions of the sponsor
The sponsor reviewed the resignation documents of Mr. Zhang Hewen, the confidentiality agreement signed by Mr. Zhang Hewen and the company, and the past resumes of Ms. sun Guojing and Ms. Huang Xiaohua. After verification, the sponsor believes that the resignation of Mr. Zhang Hewen, the company’s core technician, for personal reasons will not have a substantive impact on the company’s technology R & D, core competitiveness and sustainable operation ability, there are no disputes or potential disputes involving service invention, and there are no significant adverse effects on the company’s business development and product innovation.
5、 Online announcement attachment
Verification opinions of Huatai United Securities Co., Ltd. on the resignation of Hob Biotech Group Corp.Ltd(688656) senior managers and core technicians and the identification of core technicians.
It is hereby announced.
Hob Biotech Group Corp.Ltd(688656) board of directors February 8, 2002
